Matrix metalloproteinase in left ventricular remodeling and heart failure

Current Cardiology Reports

Volumn 5, Issue 3, 2003, Pages 200-204

  Shastry, Suresh ^b   Hayden, Melvin R ^b   Lucchesi, Pamela A ^b   Tyagi, Suresh C ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIAC INHIBITOR OF METALLOPROTEINASE; COLLAGEN; DISINTEGRIN; INTEGRIN; MATRIX METALLOPROTEINASE; NITRIC OXIDE DONOR; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

BIOACCUMULATION; CELL DENSITY; CELL TRANSPLANTATION; CLINICAL TRIAL; COLLAGEN DEGRADATION; CONGESTIVE HEART FAILURE; ENDOCARDIUM; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME REPRESSION; GENE THERAPY; GENE TRANSFER; HEART LEFT VENTRICLE; HEART MUSCLE; HUMAN; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEOMICS; REGULATORY MECHANISM; REVIEW; TREATMENT PLANNING; ENZYME ASSAY; ENZYMOLOGY; HEART VENTRICLE REMODELING; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ENZYME TESTS; HEART FAILURE, CONGESTIVE; HUMANS; MATRIX METALLOPROTEINASES; MYOCARDIUM; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR REMODELING;

EID: 0038411366     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-003-0049-5     Document Type: Review

References (52)

1. Tyagi SC: Proteinases and myocardial extracellular matrix turnover. Mol Cell Biochem 1997, 168:1-12.
2. Loechel F, Gilpin BJ, Engvall E, et al.: Human ADAM12 (meltrin á) is an active metalloproteinase. J Biol Chem 1998, 273:16993-16997.
3. Hayden MR, Tyagi SC: Arteriogenesis: angiogenesis within unstable atherosclerotic plaque-interactions with extracellular matrix, Curr Intervent Cardiol Report 2000, 2:218-227.
4. Nagase H, Woessner JF, Matrix metalloproteinase. J Biol Chem 1999, 274:21491-21494.
5. Wolfsberg TG, White JM: ADAMs in fertilization and development. Devel Biol 1996, 180:389-401.
6. Tyagi SC: Dynamic role of extracellular matrix metalloproteinases in heart failure. Cardiovasc Pathol 1998, 7:153-159.
7. Hunt MJ, Aru GM, Hayden MR, et al.: Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol 2002, 283:L239-L245.
8. Faury G, Ristori MT, Verdetti J, et al.: Effect of elastin peptides on vascular tone. J Vasc Res 1995, 32:112-119.
9. Hunt MJ, Tyagi SC: Peroxisome proliferators compete and ameliorate homocysteine-mediated endocardial endothelial cells activation. Am J Physiol (Cell Physiol) 2002, 283:C1073-C1O79.
10. Mujumdar VS, Aru GM, Tyagi SC: Induction of oxidative stress by homocysteine impairs endothelial function. J Cell Biochem 2001, 82:491-500.
11. Miller A, Mujumdar V, Palmer L, et al.: Reversal of EE dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 2002, 15:157-163.
12. Michel J-B, Salzmann J-L, Nlom MO, et al.: Morphometric analysis of collagen network and plasma perfused capillary bed in the myocardium of rats during evolution of cardiac hypertrophy. Basic Res Cardiol, 1986, 81:142-154.
13. Amann K, Breitbach M, Ritz E, Mall G: Myocyte/capillary mismatch in the heart of uremic patients, J Am Soc Nephrol 1998, 9:1018-1022.
14. Miller A, Mujumdar V, Shek E, et al.: Hyperhomocysteinemia induces multiorgan damage. Heart Vessels 2000, 15:135-143.
15. Patel R, Nagueh SF, Tsybouleva N, et al.: Simavastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001, 104:317-324.
16. Capasso JM, Robinson TE, Aneversa P: Alterations in collagen cross-linking impair myocardial contractility in the mouse heart. Cir Res 1989, 65:1657-1664.
17. Matsubara LS, Matsubara BB, Okashi MP, et al.: Alterations in myocardial collagen content affect rat papillary muscle function. Am J Physiol 2000, 279:H1534-H1539.
18. Aimes RT, Quigley JP: MMP-2 is an interstitial collagenase. J Biol Chem 1995, 270:5872-5876.
19. Senior RM, Griffin GL, Eliszar CJ, et al.: Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem 1991, 266:7870-7875.
20. Rucklidge GJ, Milne G, McGaw BA, et al.: Turnover rates of different collagen types measured by isotope ratio mass spectrometry. Biochim Biophys Acta 1992, 11:1156-1157.
21. Vaitkevius PV, Lane M, Spurgeon H, et al.: A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A 2001, 98:1171-1175.
22. Asif M, Egan J, Vaan S, Jyothirmayi GN, et al.: An advanced glycation endproduct croos-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 2000, 97:2809-2813.
23. Larsson H, Sjoblom T, Dixelius J, Ostman A, et al.: Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 2000, 60:6723-6729.
24. Mansell A, Reincke A, et al.: The serine protease inhibitor antithrombin II inhibits LPS-mediated NFkB activation by TLR-4. FEBS Lett 2001, 508:313-317.
25. Moses MA, Langer R: A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem 1991, 47:230-235.
26. Hayakawa T, Yamashita K, Tanzawa K, et al.: Growth-promoting activity of TIMP-1 for a wide range of cells. FEBS Lett 1992, 298:29-32.
27. Tyagi SC, Meyer L, Kumar SG, et al.: Induction of tissue inhibitor of metalloproteinase and its mitogenic response to endothelial cells in human atherosclerotic and restenotic lesions. Canadian J Cardiol 1996, 12:353-362.
28. Nemeth JA, Goolsby CL: TIMP-2, a growth-stimulatory protein from SV40 transformed human fibroblasts. Exp Cell Res 1993, 207:376-382.
29. Baker AH, Zaltsman AB, George SJ, Newby AC: Divergent effects of TIMP-1, -2, -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998, 101:1478-1487.
30. Tummalapalli CM, Heath BJ, Tyagi SC: Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem 2001, 80:512-521.
31. Tyagi SC, Ratajska A, Weber KT: Myocardial matrix metalloproteinases: localization and activation. Mol Cell Biochem 1993, 126:49-59.
32. Radomski A, Sawicki G, Olson DM, Radomski MW: The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia-induced lung injury in newborn rats. Br J Pharmacol 1998, 125:1455-1462.
33. Tyagi SC, Kumar SG, Borders S: Reduction-oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells. J Cell Biochem 1996, 61:139-151.
34. Frears ER, Zhang Z, Blake DR, et al.: Inactivation of TIMP-1 by peroxynitrite. FEBS Lett 1996, 381:21-24.
35. Stricklin GP, Hoidal JR: Oxidant-mediated inactivation of TIMP. Matrix Suppl 1992, 1:325.
36. Shabani F, McNeil J, Tippett L: The oxidative inactivation of TIMP-1 by HOCI is suppressed by ant-rheumatic drugs. Free Radic Res 1998, 28:115-123.
37. Rohde LE, Ducharme A, Arroyo LH, et al.: MMP inhibitors attenuates early LV enlargement in experimental MI in mice. Circulation 1999, 99:3063-3070.
38. Spinale FG, Coker ML, Krombach SR, et al.: MMP inhibition during congestive heart failure. Circ Res 1999, 85:364-376.
39. Hoppeler H, Kayar SR: Capillary and oxidative capacity of muscles. News in Physiol Sci 1988, 3:113-116.
40. Cox M, Sood H, Hunt M, et al.: Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am J Physiol 2002, 282:H1197-H1205.
41. Pinsky DJ, Patton S, Mesaros S, et al.: Mechanical transduction of NO synthesis in the beating heart. Circ Res 1997, 81:372-379.
42. Babior BM: NADPH oxidase: an update. Blood 1999, 93:1464-1476.
43. Roos D, Wening RS, Wyss SR: Protection of human neutrophils by endogenous catalase: studies with cells from catalase-deficient individuals. J Clin Invest 1980, 65:1515-1522.
44. Laycock SK, McMurray J, Kane KA, Parratt JR: Effects of chronic norepinephrine administration on cardiac function in rats, J Cardiovasc Pharmacol 1995, 26:584-589.
45. Givertz MM, Colucci WS: New targets for heart-failure therapy: endothelin, inflammatory cytokines, an oxidative stress. Lancet 1998, 352:SI34-SI38.
46. Chen CY, Huang YL, Lin TH: Association between oxidative stress and cytokine production in nickel-treated rats. Arch Biochem Biophys 1998, 15:127-132.
47. Tyagi SC, Hayden MR, Hall JE: Role of angiotensin in angiogenesis and cardiac fibrosis in heart failure. Angiotensin II receptor blockade: physiological and clinical implications. In Progress in Experiential Cardiology, edn 2. Edited by Dhalla NS, Zahradka P, Dixon IMC, Beamish RE. Boston: Kluwer Academic Publishers; 1998:537-549.
48. Varin R, Mulder P, Tamion F, et al.: Improvement of endothelial function by chronic ACEI in heart failure: role of NO, prostanoids, oxidant stress and bradykinin. Circulation 2000, 102:351-356.
49. Li P, Chappell MC, Ferrario CM, Brosnihan KB: Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing NO. Hypertension 1997, 29:394-400.
50. Zhang H, Schmeisser A, Garlichs CD, et al.: Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH/NADPH-oxidases. Cardiovasc Res 1999, 44:215-222.
51. Taylor DA, Atkins BZ, Hungspreugs P, et al.: Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 1998, 4:929-933.
52. Ducharme A, Frantz S, Aikawa M, et al.: Targeted deletion of MMP-9 attenuates LV enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000, 106:55-62.